12,743 Shares in MBX Biosciences, Inc. (NYSE:MBX) Purchased by BIT Capital GmbH

BIT Capital GmbH acquired a new position in shares of MBX Biosciences, Inc. (NYSE:MBX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,743 shares of the company’s stock, valued at approximately $235,000.

Other hedge funds have also added to or reduced their stakes in the company. Corebridge Financial Inc. purchased a new stake in shares of MBX Biosciences during the 4th quarter worth approximately $103,000. JPMorgan Chase & Co. purchased a new stake in MBX Biosciences in the fourth quarter worth $168,000. Rhumbline Advisers bought a new stake in shares of MBX Biosciences in the fourth quarter valued at $175,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of MBX Biosciences during the 3rd quarter valued at $278,000. Finally, Point72 Asset Management L.P. bought a new position in shares of MBX Biosciences during the 3rd quarter worth $405,000.

Insider Transactions at MBX Biosciences

In other MBX Biosciences news, Director Carl L. Gordon acquired 143,170 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was bought at an average cost of $10.84 per share, with a total value of $1,551,962.80. Following the acquisition, the director now owns 3,255,000 shares in the company, valued at approximately $35,284,200. This represents a 4.60 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO P. Kent Hawryluk bought 50,000 shares of the stock in a transaction on Tuesday, February 4th. The shares were acquired at an average cost of $10.69 per share, for a total transaction of $534,500.00. Following the acquisition, the chief executive officer now directly owns 448,277 shares in the company, valued at approximately $4,792,081.13. This trade represents a 12.55 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 240,672 shares of company stock worth $2,555,308 over the last quarter.

MBX Biosciences Stock Down 0.5 %

Shares of MBX opened at $7.75 on Thursday. MBX Biosciences, Inc. has a fifty-two week low of $7.51 and a fifty-two week high of $27.50. The business has a 50-day moving average price of $10.00.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.